GlassScriptPhysician profile
William G Hodges
NPI 1417933599
$2,243.75
in general payments reported to CMS, 2019-2025
24 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $183 · 2021: $15.77 · 2022: $61.97 · 2023: $329 · 2024: $491 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.22 |
| Education | $123.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,062.69 | 2019-2025 | |
| Janssen Biotech, INC. | $247.51 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $179.99 | 2019-2025 | Eohilia, Entyvio |
| Allergan, INC. | $112.36 | 2019-2020 | |
| Pfizer INC. | $95.15 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $92.81 | 2023-2024 | Dupixent |
| Celltrion USA INC. | $77.17 | 2024-2025 | Vegzelma, Zymfentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.47 | 2019-2020 | |
| Genzyme Corporation | $31.83 | 2024 | |
| Lilly USA, LLC | $30.40 | 2023 | |
| Ardelyx, INC. | $27.04 | 2024 | Ibsrela |
| Qol Medical, LLC | $26.14 | 2025 | Sucraid |
| Novo Nordisk INC | $24.54 | 2025 | Wegovy |
| Endo Pharmaceuticals INC. | $22.08 | 2019 | |
| Braintree Laboratories, INC. | $20.49 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $18.88 | 2023 | Hyrimoz |
| Astrazeneca Pharmaceuticals LP | $17.82 | 2023 | Imjudo |
| Cumberland Pharmaceuticals, INC. | $15.54 | 2019 | |
| Celgene Corporation | $14.16 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.00 | 2019 | |
| Alfasigma USA, INC. | $13.14 | 2020 | |
| Olympus America INC. | $11.91 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.63 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.